Imagine a future where breast cancer screening isn’t a one-size-fits-all approach, but a tailored journey based on your unique risk factors. That future is closer than you think. While mammograms are a powerful tool, they’re not foolproof, especially for women with dense breast tissue. But here’s where it gets controversial: should we rely solely on mammograms, or is it time to embrace additional imaging techniques for those at higher risk? Let’s dive into the latest research and debates shaping the future of breast imaging.
The Dense Breast Dilemma
For the 60% of women in Europe enrolled in national breast cancer screening programs, mammograms offer a reassuring glimpse into their breast health. But what about the 30% with dense breasts and the 10% with extremely dense breasts? These women face a unique challenge: their dense tissue can mask tumors, making early detection on mammograms more difficult. At the 2025 Society of Breast Imaging (SBI) Symposium, Prof. Ruud Pijnappel, a leading expert in breast radiology, shed light on this critical issue. He emphasized the need for personalized screening protocols, moving away from the traditional one-size-fits-all approach.
The Power of Supplemental Imaging
Supplemental imaging, such as MRI, contrast-enhanced mammography (CEM), and automated whole breast ultrasound (ABUS), has emerged as a potential solution. For instance, the DENSE clinical trial in the Netherlands, involving over 40,000 women with extremely dense breasts, demonstrated that supplemental MRI significantly reduced interval cancers—those found between screenings. The interval-cancer rate dropped from 5.06 per 1,000 screenings with mammography alone to 0.83 per 1,000 with MRI. But here’s the catch: the cost and availability of MRI scanners have limited its widespread adoption, with only Estonia incorporating it into their national screening program.
Ongoing Trials: Searching for the Best Approach
Several clinical trials are now exploring more cost-effective and accessible alternatives. The DENSE 2 trial, launched in 2024, is comparing CEM and abbreviated breast MRI (AB-MRI) to mammography alone in 36,000 women with dense breasts. Similarly, the BRAID trial in the UK is evaluating CEM, AB-MRI, and ABUS in nearly 9,400 women. Early results from BRAID show that CEM and AB-MRI detected smaller invasive tumors compared to ABUS, highlighting the potential of these technologies.
AI: The Game-Changer?
Artificial intelligence (AI) is also stepping into the spotlight. The ScreenTrustMRI trial in Sweden is using an AI tool, AISmartDensity, to identify women at high risk of delayed cancer detection due to false-negative mammograms. By analyzing mammographic density, potential masking, and other risk factors, the AI tool selected only 6.9% of over 59,300 women for supplemental MRI. This targeted approach not only detected cancers more efficiently but also reduced costs, making it a promising avenue for personalized screening.
The Future is Personalized
Prof. Pijnappel envisions a future where breast cancer screening is tailored to individual risk profiles. “Not every woman with dense breast tissue will develop cancer,” he notes. “And breast cancer occurs in women with average tissue density and fatty breasts too.” By extending screening intervals for low-risk women and offering more frequent exams to high-risk individuals, we can optimize resources and improve outcomes. But this raises a critical question: How do we balance the benefits of personalized screening with the logistical and financial challenges of implementing such a system?
What Do You Think?
Is personalized breast cancer screening the way forward, or are we overcomplicating a system that already works for many? Should governments invest in supplemental imaging for high-risk women, even if it means higher costs? Share your thoughts in the comments—let’s spark a conversation that could shape the future of breast health.
